Tag Archives: Capricor Therapeutics

Capricor Therapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell- and exosome-based therapeutics for the treatment and...

Capricor Therapeutics, a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other...

Four of six critically ill COVID-19 (coronavirus) patients significantly improved after receiving an experimental therapeutic designed to reduce inflammation, a major cause of death from this...

We are seeking a highly motivated scientific leader with experience in cell therapy and exosomes to develop our exosome platform. This position is...

Capricor Therapeutics announced today that it has added seven new patent applications to its existing Exclusive License Agreements with Cedars-Sinai Medical Center for technologies related to cardiosphere-derived cells (CDCs) and CDC-derived extracellular vesicles, including exosomes. The Exclusive License Agreements with Cedars-Sinai ...

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) is one of the most sensitive, economical and widely used methods for evaluating gene expression. However, the utility of this method continues to be undermined by a number of challenges including normalization using appropriate ...

The era of using extracellular vesicles (EVs) and exosomes for regenerative medicine applications in the clinic is here. The team at Capricor Therapeutics, Inc. utilized a cardiosphere-derived stem-like cell culturing process to manufacture secreted EVs present in conditioned medium for ...

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company developing biological therapies for cardiac and other serious medical conditions, today announced that it has been awarded a grant of up to $4.2 million from the National Institutes of Health to ...

Capricor Therapeutics, Inc.  a clinical-stage biotechnology company developing biological therapies for cardiac and other serious medical conditions, today announced that the U.S. Department of Defense (DoD) has awarded the company a grant1 in the amount of approximately $2.4 million to ...

from The Market Digest by Robert Westfall Capricor Therapeutics Inc (CAPR) was Initiated by ROTH Capital to “Buy”. ROTH Capital advised their investors in a research report released on Jun 15, 2016. Capricor Therapeutics Inc opened for trading at $3.31 ...